Skip to main content

Table 1 General demographic and clinical data; mean ± SD and n (%)

From: Circulatory efficiency in patients with severe aortic valve stenosis before and after aortic valve replacement

Subjects AS patients (n = 41) Healthy controls (n = 10) p-value
Age (years) 67 ± 9 62 ± 10 0.131
Male gender, n (%) 21 (51%) 5 (50%) 0.945
Body mass index (kg/m2) 28 ± 4.2 25 ± 3.6 0.029
BSA (m2) 2 ± 0.24 2 ± 0.2 0.169
Duration between AVR and Visit 2 (d) 125 ± 38
Prothesis data
 Prosthesis size [mm] 23 ± 2
 Biological prosthesis, n (%) 39 (95%)
 Prosthesis type Medtronic biological, n (%) 1 (2%)
 Prosthesis type Medtronic mechanical, n (%) 1 (2%)
 Prosthesis type Edwards, n (%) 9 (22%)
 Prosthesis type St Jude Medical Regent, n (%) 1 (2%)
 Prosthesis type Trifecta, n (%) 21 (51%)
 Prosthesis type CE Perimount Magna Ease, n (%) 8 (20%)
Risk factors
 Bicuspid aortic valve, n(%) 31 (76%) 0 (0%) < 0.001
 Dyslipidaemia, n(%) 20 (49%) 4 (40%) 0.618
 Diabetes mellitus, n(%) 4 (10%) 1 (10%) 0.981
 CCS III-VI, n(%) 3 (7%) 0 (0%) 0.378
 NYHA III-VI, n(%) 18 (35%) 0 (0%) 0.009
 Arterial hypertension, n(%) 29 (71%) 4 (40%) 0.068
Medical treatment
 Betablocker, n (%) 17 (42%) 3 (30%) 0.506
 Calcium antagonist, n (%) 4 (10%) 1 (10%) 0.981
 Diuretics, n (%) 11 (27%) 2 (20%) 0.657
 ARB, n (%) 9 (22%) 2 (20%) 0.893
 ACE-I, n (%) 11 (29%) 0 (0%) 0.064
  1. BSA body surface area, RF regurgitation fraction, CCS Canadian Cardiovascular Society, NYHA New York Heart Association, ARB angiotensin receptor blocker, ACE-I angiotensin converting encyme inhibitor